August 22, 2019
Sickle cell disease (SCD) is a single recessive gene disorder causing a debilitating systemic syndrome characterised by chronic anaemia, acute painful episodes, organ infarction and chronic organ damage and by a significant reduction in life expectancy
More recently, population migration has meant that SCD now has a worldwide distribution and that a substantial number of children are born with the condition in higher-income areas, including large parts of Europe and North and South America.
Newborn screening, systematic clinical follow-up and prevention of sepsis and organ damage have led to an increased life expectancy among people with SCD in many such countries; however, in resource-limited settings where the majority continue to be born, most affected children continue to die in early childhood, usually undiagnosed, due to the lack of effective programmes for its early detection and treatment.
As new therapies emerge, potentially leading to disease amelioration, it is of paramount importance that the significant burden of SCD in resource-poor countries is properly recognised.
Sickle cell disease (SCD) has recently been recognised as a problem of major public-health significance by the World Health Organization. Despite the fact that 70% of sufferers live in Africa, the understanding and management of this condition have been sabotaged by some greedy pharmaceutical companies in making gains from the pains of others.
African countries need to focus on enacting laws that will sanction these companies that claims to cure Sickle cell disorder. Interventions on areas that will lead to the maximum impact on the lives of Africans should be of priority. Epidemiological and clinical background of SCD, with emphasis on Africa, should focus on providing the necessary evidence base for improving the management of African patients and not the cure because sickle cell disorder has no cure, but can only be managed.
Research should be done on malaria, bacterial and viral infections and cerebrovascular accidents, these areas may lead to a significant improvement in SCD-related morbidity and mortality in Africa.
As patients with high concentrations of foetal haemoglobin appear to be protected from all but mild SCD, the various factors and pharmacological agents that might increase HbF levels need to be assessed in Africa, as options for interventions that would improve quality of life and reduce mortality.
Although the focus of health research in Africa is currently on non-infectious diseases will assume increased importance. Estimates from developed countries indicate that genetic diseases already constitute up to 40% of the requirements for chronic care in paediatric practice. Sickle cell disease (SCD) still presents a largely unrecognised health problem for millions of Africans.
Between 200,000 and 230,000 children are thought to be born with SCD in Africa every year (WHO, 1994; Diallo and Tchernia, 2002).
These estimates are based on the frequencies of the heterozygous state for the sickle cell gene (AS), which range from 2%–38%, with the highest burden of SCD estimated to be in Tanzania (WHO, 1994; Angastiniotis and Modell, 1998; Weatherall and Clegg, 2001). Although based on the results of surveys that may not be representative of entire populations, these incidences give a sense of the magnitude of the problem.
It’s so tiring living with an anemia but I must say bone marrow transplant isn’t the long lasting solution simply because the disadvantages outweigh the advantages. It not about the funds but the pains which are much more than the one you’re currently going through. Aside from the fact that it 50/50 chances yet I won’t advise you to go into it.
It’s on this note that, I want the whole world to know that SCD has no cure. That is why in EOfoundation we tell you point blank.
Sickle Cell Disease is COMPLETELY PREVENTABLE! Do NOT Settle with an incompatible partner.